Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.
about
Satraplatin: leading the new generation of oral platinum agentsLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Membrane transporters as mediators of Cisplatin effects and side effects.Caprylate-conjugated Cisplatin for the development of novel liposomal formulation.Nanocarriers for delivery of platinum anticancer drugs.DNA repair mechanisms in cancer development and therapyThe drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a dayNovel metals and metal complexes as platforms for cancer therapyInvestigations of the binding of [Pt2(DTBPA)Cl2](II) and [Pt2(TPXA)Cl2](II) to DNA via various cross-linking modes.Clinical and pharmacokinetic evaluation of satraplatin.Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer.Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers.Target-selective delivery and activation of platinum-based anticancer agents.Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug-resistant cancer by a newly synthesized Schiff base copper chelate.Advances in oral delivery of anti-cancer prodrugs.Green synthesis of bimetallic Au@Pt nanostructures and their application for proliferation inhibition and apoptosis induction in human cervical cancer cell.Metal-based antitumour drugs in the post-genomic era: what comes next?Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs.Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus.Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender DifferencesIn Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent.Anticancer platinum complexes as non-innocent compounds for catalysis in aqueous media.Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1.Synthesis and evaluation of metallocene containing methylidene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors.[Advances of DNA damage repair and Cisplatin resistance mechanisms in lung cancer].Ferrocene-Containing Impiridone (ONC201) Hybrids: Synthesis, DFT Modelling, In Vitro Evaluation, and Structure⁻Activity RelationshipsPlatinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural FactorSpectroscopic Characterization,In VitroCytotoxicity, and Antioxidant Activity of Mixed Ligand Palladium(II) Chloride Complexes Bearing Nucleobases
P2860
Q28972468-28F84D88-7A3A-444D-9F06-2B4DF324619FQ30366990-139A1A44-935E-40EF-8F7A-BF6304F216AAQ30446860-9ED72132-6A01-4966-A11E-3675261DCF37Q33962533-56EAB967-764D-4568-8C3B-E9430C22E490Q34338695-17DEE177-3D9A-43BA-87D1-36B15E1CA961Q35531287-4A017296-82DE-4824-AEA4-85B67E4DDA6CQ36957626-21D416B4-DAFA-4168-AB6D-B2A17567F222Q37137649-F3BE2B32-ADE7-4F45-A794-4E51B86A752BQ37291146-6EE43E17-5F07-4CCD-B1AF-3E23BA38814AQ37958009-EF5C891D-351D-4724-8511-45C52086E191Q38059212-1657BFA8-E588-4001-B6AF-5016025F93BDQ38119531-F761ACA5-38F8-4517-AE92-9C30CCA02FB1Q38183430-5F79D60B-86E9-4F73-96DE-8B5FD0E00AEDQ38523600-F385321B-19E8-4C6F-8FE6-A4F9A2B81821Q38764239-844C8A3F-7CC8-49C0-A1B9-DD519C0329B2Q38806350-4A88D4B6-4505-44D1-BECC-265C87AB83D2Q38862820-9F25ED4B-EB4A-4BDB-BBA6-EE765F9F6C04Q38900803-9C97E37E-9146-4996-9F4E-9884362DCEDFQ39732756-32D64A76-E3BC-4AFD-A7FC-CDDB425B6596Q40064331-EE173B55-3AD8-4436-80B3-F5C661108CF1Q40345569-4151A08B-D589-49A9-ADD3-0C66454AA469Q42343539-A64BACE7-AA6C-4794-99E8-3BAD1797C3F0Q43101272-592BF8A4-BF35-4CA6-896B-550E60360E83Q43196937-47E9EFB0-4C8E-4FFF-BCBB-956D9B90B1FCQ47563582-67624B30-B278-4536-A41C-D05705743E13Q50091965-5A54D788-62EA-41A7-8130-73CE1F449186Q54609190-30A26DBA-730F-42F5-9BEF-27680D4326B9Q55434155-9D7FFADD-A1B3-414A-843F-2A3B5E42EB53Q58696201-8FDBFD4A-FEB6-4A0D-AE46-51483945C936Q58993871-622EA4F1-7DF1-4F89-AC79-80412E958096Q59050147-920440D1-CEE7-47F0-9574-8CB97BA276E9
P2860
Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Broadening the clinical use of ...... s. Satraplatin and picoplatin.
@en
type
label
Broadening the clinical use of ...... s. Satraplatin and picoplatin.
@en
prefLabel
Broadening the clinical use of ...... s. Satraplatin and picoplatin.
@en
P2860
P1476
Broadening the clinical use of ...... s. Satraplatin and picoplatin.
@en
P2093
Lloyd Kelland
P2860
P304
P356
10.1517/13543784.16.7.1009
P407
P577
2007-07-01T00:00:00Z